Skip to main content

Table 1 Clinical trial of DC vaccine in glioma

From: Clinical implication of cellular vaccine in glioma: current advances and future prospects

Malignancy

Phase

Number

Study title

Identifier

Status

Interventions

Observation

DC vaccine

 Malignant glioma

I

35

Surgical resection with gliadel wafer followed by dendritic cells vaccination for malignant glioma patients (Gliadel Wafer)

NCT00576446

Completed

NA

PFS

 Malignant glioma

I

8

Vaccine therapy in treating patients with malignant glioma

NCT00612001

Completed

GAA pulsed DC

Toxicity; PFS; OS

 Recurrent malignant glioma

I/II

22

Vaccination-dendritic cells with peptides for recurrent malignant gliomas

NCT00766753

Completed

GAA pulsed DC

Toxicity; PFS; OS

 Recurrent GBM

I

20

A Study of ICT-121 dendritic cell vaccine in recurrent glioblastoma

NCT02049489

Completed

CD133 pulsed DC

Toxicity; feasibility; PFS; OS

 Recurrent GBM

I

50

Vaccine therapy in treating patients undergoing surgery for recurrent glioblastoma multiforme

NCT00890032

Completed

BTSC mRNA-loaded DC

Toxicity; feasibility; humoral and cellular immune responses

 Malignant glioma

I

71

Dendritic cell vaccine with imiquimod for patients with malignant glioma

NCT01792505

Completed

Imiquimod adjuvant

Toxicity; PFS

 Malignant glioma

I

6

Nivolumab with DC vaccines for recurrent brain tumors (AVERT)

NCT02529072

Completed

Nivolumab adjuvant

Toxicity; PFS; OS

 IDH1(R132H) mutant glioma

I

30

Safety and efficacy of IDH1 R132H-DC vaccine in gliomas

NCT02771301

Recruiting

IDH1(R132H) DC

IDH1(R132H) specific T cells; anti-IDH1(R132H) antibody level

 Newly diagnosed GBM

I

10

Personalized cellular vaccine for glioblastoma (PERCELLVAC)

NCT02709616

Active, not recruiting

TAA pulsed DC

Toxicity; PFS; OS; CD8 + and CD4 + T cell response

 Recurrent GBM

I

10

Personalized cellular vaccine for recurrent glioblastoma (PERCELLVAC2)

NCT02808364

Active, not recruiting

TAA pulsed DC

Toxicity; PFS; OS; CD8 + and CD4 + T cell response

 HGG

I

11

Cytomegalovirus (CMV) RNA-pulsed dendritic cells for pediatric patients and young adults with WHO grade IV glioma, recurrent malignant glioma, or recurrent medulloblastoma (ATTAC-P)

NCT03615404

Active, not recruiting

CMV RNA-pulsed DC

Toxicity

 Pediatric HGG

I

8

Adoptive cellular therapy in pediatric patients with high-rade gliomas (ACTION)

NCT03334305

Recruiting

GM-CSF and TTRNA-xALT plus Td vaccine without autologous HSCs

Toxicity; PFS; OS; INF γ secretion

 DIPG

I

21

Brain stem gliomas treated with adoptive cellular therapy during focal radiotherapy recovery alone or with dose-intensified temozolomide (Phase I) (BRAVO)

NCT03396575

Recruiting

GM-CSF and TTRNA-xALT plus Td vaccine without autologous HSCs

Toxicity; feasibility; PFS; OS; immune responses

 GBM; anaplastic astrocytoma

I

20

Dendritic cell (DC) vaccine for malignant glioma and glioblastoma

NCT01808820

Active, not recruiting

Post-DC Vaccine therapy, administered lysate of tumor

Toxicity; PFS; OS; MDSC levels and blood counts

 Newly diagnosed GBM

I

42

Vaccine therapy in treating patients with newly diagnosed glioblastoma multiforme (ATTAC)

NCT00639639

Active, not recruiting

pp65-shLAMP DC and Td

Toxicity; feasibility; PFS; OS; humoral and cellular immune responses

 GBM

I

39

Phase I study of a dendritic cell vaccine for patients with either newly diagnosed or recurrent glioblastoma

NCT02010606

Active, not recruiting

Bevacizumab adjuvant

Toxicity; PFS; OS; cytotoxic T cell activity; tumor stem cell antigen expression

 GBM; DIPG

I

10

Immune modulatory DC vaccine against brain tumor

NCT03914768

Enrolling by invitation

Cyclophosphamide and bevacizumab adjuvant

Toxicity; tumor response; PFS; OS

 GBM

I/II

10

Dendritic cell vaccination for patients with solid tumors

NCT01291420

Enrolling by invitation

WT1 mRNA-electroporated DC

Immunogenicity

 Pediatric glioma

I

1

Dendritic cell vaccine therapy with in situ maturation in pediatric brain tumors

NCT01902771

Terminated

Post-Vaccine, lysate of tumor and imiquimod adjuvant

Toxicity; feasibility; PFS; OS; immune response

 Medulloblastoma; PNET

I/II

1

Phase I/II: decitabine/vaccine therapy in relapsed/refractory pediatric high grade gliomas/medulloblastomas/CNS PNETs

NCT02332889

Terminated

GM-CSF and Poly-ICLC adjuvant

Tolerability

 Newly diagnosed GBM

II

11

Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme

NCT00323115

Completed

NA

Toxicity; tumor response; PFS; OS; T Cell immune responses

 Newly diagnosed GBM

II

120

Vaccine therapy for the treatment of newly diagnosed glioblastoma multiforme (ATTAC-II)

NCT02465268

Recruiting

pp65-shLAMP DC with GM-CSF and Td

PFS; OS; cytokine

 Newly diagnosed MGMT unmethylated HGG

II

48

Immunotherapy targeted against cytomegalovirus in patients with newly-diagnosed WHO grade IV unmethylated glioma (I-ATTAC)

NCT03927222

Recruiting

pp65-shLAMP DC with GM-CSF and Td

Toxicity; migration; OS

 GBM

II

100

Study of DC vaccination against glioblastoma

NCT01567202

Recruiting

Glioma stem-like cells (A2B5+) loaded DC

Tumor response; PFS; OS

 Primary GBM

II

24

A Phase II, randomized, Open-Label, parallel-group study to evaluate the efficacy and safety of autologous dendritic cell vaccination (ADCV01) as an Add-On treatment for primary glioblastoma multiforme (GBM) patients

NCT04115761

Recruiting

NA

PFS

 GBM

II/III

60

Dendritic cell immunotherapy against cancer stem cells in glioblastoma patients receiving standard therapy (DEN-STEM)

NCT03548571

Recruiting

NA

PFS; OS; immune responses

ADCTA

 Malignant glioma

I

28

Vaccine therapy in treating patients with malignant glioma

NCT00068510

Completed

NA

Toxicity; tumor response; OS; immune responses

 Pediatric malignant glioma

I

7

Vaccine therapy in treating young patients who are undergoing surgery for malignant glioma

NCT00107185

Completed

NA

Toxicity; PFS; OS

 Malignant glioma

I

8

Vaccination with dendritic cells loaded with brain tumor stem cells for progressive malignant brain tumor

NCT01171469

Completed

Imiquimod adjuvant

Toxicity; tumor response

 Newly diagnosed GBM

I

21

Vaccine therapy and temozolomide in treating patients with newly diagnosed glioblastoma

NCT01957956

Active, not recruiting

NA

Toxicity; tumor response; PFS; OS

 Recurrent GBM

I

20

Vaccine therapy in treating patients with recurrent glioblastoma

NCT03360708

Recruiting

NA

Toxicity; tumor response; PFS; OS

 Recurrent GBM

I

40

Pembrolizumab and a vaccine (ATL-DC) for the treatment of surgically accessible recurrent glioblastoma

NCT04201873

Recruiting

Pembrolizumab and poly ICLC adjuvant

Toxicity; PFS; OS; Cell cycle-related signature; TIL density; TCR Clonality

 GBM

I/II

10

Clinical study of a dendritic and glioma cells fusion vaccine with IL-12 for treatment-naïve GBM patients

NCT04388033

Recruiting

IL-12 adjuvant

Toxicity; PFS; OS

 HGG

I/II

25

Autologous dendritic cells and metronomic cyclophosphamide for relapsed high-grade gliomas in children and adolescents

NCT03879512

Recruiting

Cyclophosphamide adjuvant

Toxicity; PFS; OS; Treg; CTL; cytokine

 GBM

II

87

Dendritic cell cancer vaccine for high-grade glioma (GBM-Vax)

NCT01213407

Completed

Trivax adjuvant

PFS; OS

 GBM

II

26

Efficacy & safety of autologous dendritic cell vaccination in glioblastoma multiforme after complete surgical resection

NCT01006044

Completed

NA

Toxicity; PFS; OS; humoral/cellular response

 LGG

II

18

Vaccine for patients with newly diagnosed or recurrent low-grade glioma

NCT01635283

Active, not recruiting

NA

PFS; OS

 GBM

II

50

Dendritic cell-based tumor vaccine adjuvant immunotherapy of human glioblastoma multiforme

NCT02772094

Active, not recruiting

NA

Toxicity; PFS; OS

 Newly diagnosed  GBM

II

136

Efficiency of vaccination with lysate-loaded dendritic cells in patients with newly diagnosed glioblastoma (GlioVax)

NCT03395587

Recruiting

NA

PFS; OS

 Glioma

II

60

Dendritic cell vaccine for patients with brain tumors

NCT01204684

Active, not recruiting

Poly-ICLC adjuvant

PFS; OS

  1. DC dendritic cell; ADCTA autologous DC/tumor antigen vaccine; GAA glioma-associated antigen; GM-CSF granulocyte macrophage-colony stimulating factor; MAGE-A1 melanoma antigen gene-A1; MAGE-A3 melanoma antigen gene-A3; CMV cytomegalovirus; SAA stem-like cells associated antigens; TAA tumor-associated antigens; DIPG diffuse intrinsic pontine glioma; MDSC myeloid derived suppressor cell; Poly-ICLC polyinosinic-polycytidilic acid; GAAs glioma-associated antigens; PNET primitive neuroectodermal tumor; GBM glioblastoma; HGG high-grade glioma; LGG low-grade glioma; NA not applicable; Td tetanus-diphtheria; CTL cytotoxic T cell; HSCs hematopoietic stem cells; TCR T cell receptor; TIL tumor infiltrating lymphocyte; WT1 Wilms’ Tumor Gene